Imgenex had been involved in the field of novel reagents for the scientific study of human biology and disease and the production of new diagnostic assays and potential therapies. These novel reagents included antibodies, gene and protein expression systems and arrays of various cells and tissues for use in studies of functional genomics. In October 2013, it was announced that Novus Biologicals had acquired Imgenex Corporation - a firm specializing in reagents for Life Science research with particular strength in the areas of Innate and Adaptive Immunity, Apoptosis and Cancer. The acquisition of Imgenex expanded Novus Biologicals⢠product catalog, which includes more than 200,000 unique Life Sciences products. IImgenex had offered products for studying Toll-like Receptor (TLRsÂ) and Innate Immunity. TLRs are a class of proteins that play a key role in the innate immune system, as well as the digestive system. Imgenex⢠products and expertise also included research, in the cancer space, apoptosis, signaling pathways, cellular aging, metabolic and infectious disea
